ArticlePloS one2020
The art of obtaining a high yield of cell-free DNA from urine.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 59 citations in OpenAlex.
- Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women.PloS one · 2021Trial
- Urinary DNA Extraction in Uro-Oncology and Selected Non-Urological Malignancies: A Narrative Review.Journal of clinical medicine · 2026Review
- Liquid biopsies in precision oncology for older adults with cancer.NPJ precision oncology · 2026Review
- Unlocking the potential of urine-based liquid biopsy through improved reporting and standardization.Nature reviews. Cancer · 2026Article
- Impact of preanalytical variables on urinary cell-free DNA quality: Centrifugation, EDTA concentration, storage and thawing strategies.PloS one · 2026Article
- Evaluation of urinary cfDNA workflows for the molecular profiling of malignant disease.iScience · 2025Article
- Urine cf-nucleosomes: A non-invasive window into human physiology and disease.Cell genomics · 2025Article
- Leveraging sequences missing from the human genome to diagnose cancer.Communications medicine · 2025Article
- Unlocking the potential of tumor-derived DNA in urine for cancer detection: methodological challenges and opportunities.Molecular oncology · 2025Review
- Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review).International journal of oncology · 2025Review
- Improved Nucleic Acid Amplification Test for the Diagnosis of Onchocerciasis and Its Use for Detection of Circulating Cell-free DNA.The Journal of infectious diseases · 2025Article
- From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer.Current oncology reports · 2024Review
- Stability, enrichment, and quantification of total and HPV16-specific IgG present in first-void urine.Scientific reports · 2024Article
- Concentration strategies for spiked and naturally present biomarkers in non-invasively collected first-void urine.European journal of medical research · 2024Article
- Blazing the trail for innovative tuberculosis diagnostics.Infection · 2024Review
- The Challenge to Stabilize, Extract and Analyze Urinary Cell-Free DNA (ucfDNA) during Clinical Routine.Diagnostics (Basel, Switzerland) · 2023Article
- Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids.Human genomics · 2023Article
- Extrinsic and intrinsic preanalytical variables affecting liquid biopsy in cancer.Cell reports. Medicine · 2023Review
- A Novel, Highly Sensitive Nucleic Acid Amplification Test Assay for the Diagnosis of Loiasis and its Use for Detection of Circulating Cell-Free DNA.The Journal of infectious diseases · 2023Article
- Network approach in liquidomics landscape.Journal of experimental & clinical cancer research : CR · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although liquid biopsies offer many advantages over tissue biopsies, they are not yet standard practice. An important reason for the lack of implementation is the unavailability of well standardized techniques and guidelines, especially for pre-analytical conditions which are an important factor causing the current sensitivity issues. To overcome these limitations, we investigated the effect of several pre-analytical conditions on the concentration of cell-free DNA (cfDNA) and cellular genomic DNA (gDNA) contamination. Urine samples from healthy volunteers (HVs) and cancer patients were collected and processed according to specific pre-analytical conditions. Our results show that in samples with a relatively small volume more than 50% of the cfDNA can be found in the first 50 mL of the urine sample. The total DNA concentration increased again when samples were collected more than 3.5 hours apart. Adding preservative to urine samples is recommended to obtain high concentrations of cfDNA. To remove the cellular content, high speed centrifugation protocols as 4,000g 10min or 3,000g 15min are ideal for urine collected in cfDNA Urine Preserve (Streck). Although this study was a pilot study and needs to be confirmed in a larger study population, clear trends in the effect of several pre-analytical conditions were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.